Merola, J., H. Sofen, D. Thaci, C. Paul, S. Imafuku, . S. Banerjee, and A. Armstrong. “Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Versus Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Efficacy Analysis by Baseline Disease Characteristics From the Phase 3 POETYK PSO-1 and PSO-2 Trials”. SKIN The Journal of Cutaneous Medicine, vol. 5, no. 6, Nov. 2021, p. s36, doi:10.25251/skin.5.supp.36.